- Home
- LGVN vs PMN Comparison
LGVN vs PMN Comparison
Compare LGVN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- PMN
- Stock Information
- Founded
- LGVN 2014
- PMN 2004
- Country
- LGVN United States
- PMN Canada
- Employees
- LGVN N/A
- PMN N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- PMN Pharmaceuticals and Biotechnology
- Sector
- LGVN Health Care
- PMN Health Care
- Exchange
- LGVN Nasdaq
- PMN Nasdaq
- Market Cap
- LGVN 23.4M
- PMN 17.5M
- IPO Year
- LGVN 2021
- PMN N/A
- Fundamental
- Price
- LGVN $1.24
- PMN $0.52
- Analyst Decision
- LGVN Strong Buy
- PMN Strong Buy
- Analyst Count
- LGVN 3
- PMN 2
- Target Price
- LGVN $8.67
- PMN $4.50
- AVG Volume (30 Days)
- LGVN 123.3K
- PMN 59.5K
- Earning Date
- LGVN 05-08-2025
- PMN 05-12-2025
- Dividend Yield
- LGVN N/A
- PMN N/A
- EPS Growth
- LGVN N/A
- PMN N/A
- EPS
- LGVN N/A
- PMN N/A
- Revenue
- LGVN $2,225,000.00
- PMN N/A
- Revenue This Year
- LGVN N/A
- PMN N/A
- Revenue Next Year
- LGVN $17.49
- PMN N/A
- P/E Ratio
- LGVN N/A
- PMN N/A
- Revenue Growth
- LGVN 127.50
- PMN N/A
- 52 Week Low
- LGVN $0.77
- PMN $0.47
- 52 Week High
- LGVN $6.40
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- LGVN 37.16
- PMN 46.07
- Support Level
- LGVN $1.25
- PMN $0.47
- Resistance Level
- LGVN $1.37
- PMN $0.61
- Average True Range (ATR)
- LGVN 0.09
- PMN 0.06
- MACD
- LGVN -0.01
- PMN 0.00
- Stochastic Oscillator
- LGVN 1.75
- PMN 35.71
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.